Cargando…
Limiting antipsychotic drugs in dementia
Most patients with dementia have behavioural and psychological symptoms. The first-line treatments for these symptoms are not drugs, but behavioural and psychological interventions Antipsychotic drugs are widely prescribed for people living with dementia. This is despite a high adverse effect burden...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
NPS MedicineWise
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900276/ https://www.ncbi.nlm.nih.gov/pubmed/33664543 http://dx.doi.org/10.18773/austprescr.2020.078 |
_version_ | 1783654190377074688 |
---|---|
author | Macfarlane, Stephen Cunningham, Colm |
author_facet | Macfarlane, Stephen Cunningham, Colm |
author_sort | Macfarlane, Stephen |
collection | PubMed |
description | Most patients with dementia have behavioural and psychological symptoms. The first-line treatments for these symptoms are not drugs, but behavioural and psychological interventions Antipsychotic drugs are widely prescribed for people living with dementia. This is despite a high adverse effect burden and limited evidence of efficacy Most behavioural and psychological symptoms will subside spontaneously within six months. Trials of deprescribing are therefore recommended Behaviours should be seen as symptoms that have an underlying cause. Treatment should target these causes, rather than the resultant behaviours |
format | Online Article Text |
id | pubmed-7900276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | NPS MedicineWise |
record_format | MEDLINE/PubMed |
spelling | pubmed-79002762021-03-03 Limiting antipsychotic drugs in dementia Macfarlane, Stephen Cunningham, Colm Aust Prescr Article Most patients with dementia have behavioural and psychological symptoms. The first-line treatments for these symptoms are not drugs, but behavioural and psychological interventions Antipsychotic drugs are widely prescribed for people living with dementia. This is despite a high adverse effect burden and limited evidence of efficacy Most behavioural and psychological symptoms will subside spontaneously within six months. Trials of deprescribing are therefore recommended Behaviours should be seen as symptoms that have an underlying cause. Treatment should target these causes, rather than the resultant behaviours NPS MedicineWise 2021-02-01 2021-02 /pmc/articles/PMC7900276/ /pubmed/33664543 http://dx.doi.org/10.18773/austprescr.2020.078 Text en (c) NPS MedicineWise http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License. |
spellingShingle | Article Macfarlane, Stephen Cunningham, Colm Limiting antipsychotic drugs in dementia |
title | Limiting antipsychotic drugs in dementia |
title_full | Limiting antipsychotic drugs in dementia |
title_fullStr | Limiting antipsychotic drugs in dementia |
title_full_unstemmed | Limiting antipsychotic drugs in dementia |
title_short | Limiting antipsychotic drugs in dementia |
title_sort | limiting antipsychotic drugs in dementia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7900276/ https://www.ncbi.nlm.nih.gov/pubmed/33664543 http://dx.doi.org/10.18773/austprescr.2020.078 |
work_keys_str_mv | AT macfarlanestephen limitingantipsychoticdrugsindementia AT cunninghamcolm limitingantipsychoticdrugsindementia |